Product Description: Sembragiline (EVT 302) is a potent, selective and reversible monoamine oxidase B (MAO-B) inhibitor. Sembragiline reduces the metabolism of dopamine and other amine neurotransmitters by inhibiting the activity of the MAO-B enzyme, thereby potentially increasing the concentration of these neurotransmitters in the brain. Inhibition of the MAO-B enzyme also reduces the formation of toxic reactive oxygen species (ROS) that play a role in the pathological process of AD. Sembragiline has good oral activity and blood-brain barrier permeability. Sembragiline can be used in studies of AD, especially in patients with AD who show increased MAO-B activity[1].
Applications: Neuroscience-Neurodegeneration
Formula: C19H19FN2O3
References: [1]Sturm S, et al. Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer’s disease and elderly controls after oral administration of sembragiline[J]. European journal of nuclear medicine and molecular imaging, 2017, 44: 382-391.
CAS Number: 676479-06-4
Molecular Weight: 342.36
Research Area: Neurological Disease
Target: Monoamine Oxidase;Reactive Oxygen Species
Deutsch
English
